Does it mean anything when a corporate insider and a member of Congress buy the same stock?

It is weak corroboration, not confirmation. The two groups file under different regimes for different reasons and almost never coordinate. The overlap is most interesting when the insider purchase is an open-market buy rather than an option exercise, and when the combined amount is large relative to the company's market capitalisation. Both filings are historical: Form 4 arrives within two business days, but a Congressional report can be up to 45 days late.

Why rank these stocks by percentage of market cap instead of by the number of buyers?

Because counting filings favours large companies permanently. A mega-cap has more officers, more directors and more index-driven attention, so it accumulates more filings regardless of conviction. Expressing the combined purchase value as a percentage of market capitalisation asks a different question: how big was this relative to the company being bought?

Can I act on this overlap?

Not as a timing signal. The Congressional half of the data became public up to 45 days after the trade, so any figure measured from the disclosed transaction price describes the filer's outcome rather than a follower's. Treat the overlap as a research starting point — a reason to read the filings and the company — not as an entry trigger.

Why are sales excluded from a combined insider-and-Congress ranking?

Purchases have a narrower set of explanations than sales. An insider sells for diversification, tax, divorce, a house purchase, or under a pre-scheduled 10b5-1 plan, none of which reflect a view on the company. Buying with your own money in a company you already have concentrated exposure to is harder to explain any other way.

When corporate insiders and Congress buy the same stock: what the overlap does and doesn't tell you

Two disclosure regimes, two very different sets of motives. When a company officer and a member of Congress both buy the same stock, is the overlap a signal — or just arithmetic? Here's how to read it honestly.

2026-08-10 · 12 min read · By Insider Option

There are two large, mandatory, public disclosure regimes covering stock purchases by people with unusual proximity to information. Corporate officers and directors file SEC Form 4 within two business days of trading their own company's shares. Members of Congress file Periodic Transaction Reports under the STOCK Act, with up to 45 days of latitude.

These groups are almost entirely disjoint. A CFO buying her own company's stock and a senator buying the same ticker have no reason to be coordinating, and in the overwhelming majority of cases they are not. Which is exactly what makes the overlap interesting — and also what makes it easy to overstate.

Why the overlap is worth looking at

The academic case for insider buying is well established and covered in our review of the research: open-market purchases by officers and directors have been associated with positive abnormal returns, concentrated in smaller companies, and the effect is strongest when several unaffiliated insiders buy in the same window. That last finding is the important one here. Cluster buying beats single-insider buying because it is harder to explain away as one person's idiosyncratic circumstances.

The logic of looking at Congressional purchases alongside insider purchases is an extension of the same idea. Two independent parties, subject to different disclosure rules, with different information sets, arriving at the same conclusion is weakly more informative than one. Not because legislators are good analysts — the evidence on that is far thinner than the internet suggests, and we have written about why most politician rankings are wrong — but because it is a second, unrelated reason for the same name to surface.

Why we rank by size relative to the company

The obvious way to build a list like this is to count filings: which tickers appear most often across both sets? That method is broken, and predictably so.

A company with a $200B market capitalisation has more officers and directors than one at $200M. It has more institutional coverage, more index inclusion, more reason for a legislator's diversified portfolio to touch it incidentally. Rank by count and you get a list of large, widely-held companies — which is to say, a list of popularity, restated.

Our Smart Money Rankings instead express the combined disclosed purchase value as a percentage of the company's market capitalisation. A $2M purchase in a $200M company is 1% of the entire business; the same purchase in a $200B company is a rounding error. The first is a statement, the second is noise, and no amount of filing-count arithmetic distinguishes them.

This choice has a consequence worth stating plainly: it tilts the list toward smaller companies. That is deliberate — it is also where the academic literature finds the insider-buying effect to be strongest, and where the market is least efficient at pricing this kind of disclosure in quickly. But it means the ranking is not a list of "the best stocks." It is a list of where disclosed buying was large relative to what was being bought.

What the numbers can't do

The amounts are estimates on the Congressional side

The STOCK Act requires transactions to be reported in ranges — "$1,001 – $15,000", "$15,001 – $50,000", and so on — not as exact sums. Any dollar total that mixes Form 4 amounts with Congressional amounts is therefore part measurement and part midpoint estimate. We use the midpoint of the disclosed range, which is the standard approach and still an approximation. Two stocks with similar totals are not precisely comparable, and a difference of a few percent between adjacent rows should not be read as meaningful.

Both halves are historical, and one is very historical

Form 4's two-business-day deadline means insider purchases are close to current. Congressional reports are not. A trade you see today may have happened six weeks ago, and the price has had six weeks to move. Any performance figure measured from the disclosed transaction price — ours included — describes what the filer's position did, not what someone acting on the filing could have captured. We set out that distinction in full on our methodology page, and it is the single most common way this kind of data gets misrepresented.

It aggregates history, not recent activity

A ranking built on all available disclosed purchases will keep a company near the top long after the buying stopped. That is a property of the method, not a bug, but it means the rank alone is incomplete. Read the last-activity date alongside it. A stock with heavy combined buying two years ago and nothing since is telling you about 2024, not about this month.

Correlation between two filings is not a mechanism

The most seductive misreading is to treat the overlap as evidence that something is known. It isn't. A legislator's portfolio may be managed by a third party with no input from them. Many Congressional filings are spousal transactions reported under the member's name because the STOCK Act requires it. An insider may be buying to satisfy a share-ownership guideline in their employment contract. None of that is visible in the filing, and none of it can be inferred from the fact that two purchases happened to land on the same ticker.

How to use a list like this without fooling yourself

Treat it as a shortlist, not a screen output. The useful output is a handful of names worth actually reading about, not a basket to buy.
Check the insider transaction type. Open-market purchases (code P) carry information. Option exercises and award-related acquisitions do not, and we filter them out for that reason — but if you are building your own version, this is the first thing that will corrupt it.
Look at whether the insiders are unaffiliated. Three purchases by one person is one decision. Three purchases by three people is three.
Weigh the amount against the buyer, not just the company. A $500k purchase by an executive earning $2M a year is a different statement from the same purchase by someone earning $20M.
Assume the Congressional leg is stale. If your thesis only works if you got in near the disclosed price, the thesis does not work.
Read the sector. Clustered buying across an entire sector after a sector-wide drawdown is a different phenomenon from buying concentrated in one company.

Where to look

Smart Money Rankings — the current combined list, with the ranking rule and its limitations stated on the page.
Corporate insider activity — Form 4 filings on their own, without the Congressional overlay.
Congressional trading data — the STOCK Act side in isolation.
How to read a Form 4 filing and how to read a Periodic Transaction Report — if you would rather verify the primary documents yourself, which is always the better option.

Informational only, and not investment advice. Past performance is not indicative of future returns. See our disclaimer for the full legal language.

Frequently asked questions

Does it mean anything when a corporate insider and a member of Congress buy the same stock?: It is weak corroboration, not confirmation. The two groups file under different regimes for different reasons and almost never coordinate. The overlap is most interesting when the insider purchase is an open-market buy rather than an option exercise, and when the combined amount is large relative to the company's market capitalisation. Both filings are historical: Form 4 arrives within two business days, but a Congressional report can be up to 45 days late.
Why rank these stocks by percentage of market cap instead of by the number of buyers?: Because counting filings favours large companies permanently. A mega-cap has more officers, more directors and more index-driven attention, so it accumulates more filings regardless of conviction. Expressing the combined purchase value as a percentage of market capitalisation asks a different question: how big was this relative to the company being bought?
Can I act on this overlap?: Not as a timing signal. The Congressional half of the data became public up to 45 days after the trade, so any figure measured from the disclosed transaction price describes the filer's outcome rather than a follower's. Treat the overlap as a research starting point — a reason to read the filings and the company — not as an entry trigger.
Why are sales excluded from a combined insider-and-Congress ranking?: Purchases have a narrower set of explanations than sales. An insider sells for diversification, tax, divorce, a house purchase, or under a pre-scheduled 10b5-1 plan, none of which reflect a view on the company. Buying with your own money in a company you already have concentrated exposure to is harder to explain any other way.

Keep reading

Do corporate insider buys predict stock returns? What the research says — When a CEO buys their own company's stock on the open market, is that a signal worth trading on? Decades of academic research say yes — with important caveats. Here's the evidence.
Does copying Congressional stock trades actually work? — An honest look at whether following politicians' disclosed trades produces excess returns — what the academic research found, why the 45-day lag matters so much, and how to test it yourself.
Which politicians are the best stock traders? Why most rankings are wrong — Leaderboards of Congress's best-performing traders circulate constantly and almost all of them are methodologically broken. Here are the six errors that inflate them, and how a defensible ranking works.